<DOC>
	<DOCNO>NCT02213003</DOCNO>
	<brief_summary>Current islet transplantation portal vein liver show unique ability islet stabilize blood glucose level prevent severe hypoglycemia select group subject Type 1 diabetes . The main limitation islet transplantation need systemic immunosuppression maintain function loss islet function time . Additionally , many study demonstrate current site transplantation liver ideal site due several factor . These factor include ( 1 ) significant liver inflammation follow islet infusion ; ( 2 ) potential life-threatening procedure-related complication bleed thrombosis ; ( 3 ) high level immunosuppressive drug GI toxins liver contributing islet toxicity ; ( 4 ) inability retrieve islet infusion ; ( 5 ) development graft dysfunction number recipient intrahepatic allogeneic autologous islet . The implantation islets omentum allow adequate engraftment islet onto omentum lead comparable superior functional clinical outcome traditional intrahepatic site .</brief_summary>
	<brief_title>Allogeneic Islet Cells Transplanted Onto Omentum</brief_title>
	<detailed_description>Islet transplantation perform subject unstable Type 1 diabetes mellitus permanent immunosuppression . Islets re-suspended autologous plasma distribute omental surface minimal invasive approach . Cell adherence achieve addition clinical-grade recombinant human thrombin reacts plasma create biocompatible , degradable gel contain islet graft . The primary efficacy endpoint proportion subject HbA1c ≤6.5 % 1 year AND free severe hypoglycemic event Day 28 Day 365 , inclusive , islet transplant . The primary safety endpoint demonstrate patient safety throughout stage trial .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Unconsciousness</mesh_term>
	<criteria>1 . Male female patient age 18 65 year age . 2 . Ability provide write informed consent . 3 . Mentally stable able comply procedure study protocol . 4 . Type1 diabetes onset disease &lt; 40 year age , insulindependence &gt; 5 year time enrollment 5 . Absent stimulate cpeptide ( &lt; 0.3ng/mL ) response mixed meal tolerance test . 6 . Involvement intensive diabetes management 7 . At least one episode severe hypoglycemia 12 month prior study enrollment . 8 . Reduced awareness hypoglycemia define Clarke score 4 OR A Hypoglycemia score great equal 90th percentile ( 1047 ) screen period ; OR Marked glycemic lability define lability index score great equal 90th percentile ( 433 mmol/L2/h•wk1 ) screening period ; OR A composite Clarke score 3 less hypoglycemia score great equal 75th percentile ( 423 ) lability index great equal 75th percentile ( 329 ) screening period . 9 . Subjects screen data 20053135 protocol accept subject eligible study . If 20053135 visit 12 month prior enrollment , Visit 2 laboratory repeat . 1 . Body Mass Index ( BMI ) &gt; 30 kg/m2 patient weight ≤50 kg . 2 . Insulin requirement &gt; 1.0 IU/kg/day &lt; 15 U/day . 3 . HbA1c &gt; 10 % . 4 . Untreated proliferative diabetic retinopathy . 5 . Blood Pressure : SBP &gt; 160 mmHg DBP &gt; 100 mmHg . 6 . Glomerular filtration rate &lt; 80 mL/min/1.73 m2 ( calculate ) . 7 . Presence history macroalbuminuria ( &gt; 300mg/g creatinine ) . 8 . Presence history panelreactive antiHLA antibody . 9 . For female subject : Serum urine Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study 4 month discontinuation . For male subject : intent procreate duration study within 4 month discontinuation unwillingness use effective measure contraception . If sexually active , subject must use least two medically accept method birth control . 10 . Presence history active infection include hepatitis B , hepatitis C , HIV , tuberculosis ( TB ) . 11 . Negative screen EpsteinBarr Virus ( EBV ) IgG determination . 12 . Invasive aspergillus , histoplasmosis , coccidioidomycosis infection within one year prior study enrollment . 13 . Any history malignancy except completely resect squamous basal cell carcinoma skin . 14 . Active alcohol substance abuse . 15 . Hb low limit normal local laboratory ; lymphopenia ( &lt; 1,000/µL ) , neutropenia ( &lt; 1,500/µL ) , thrombocytopenia ( platelet &lt; 100,000/µL ) . 16 . A history Factor V deficiency . 17 . Any coagulopathy medical condition require longterm anticoagulant therapy . 18 . Severe coexist cardiac disease , 1. recent myocardial infarction ( within past 6 month ) 2. evidence ischemia functional cardiac exam within last year ) leave ventricular ejection fraction &lt; 30 % . 19 . Persistent elevation liver function test time study entry . 20 . Symptomatic cholecystolithiasis . 21 . Acute chronic pancreatitis . 22 . Symptomatic peptic ulcer disease . 23 . Gastrointestinal disorder potentially interfere ability absorb oral medication . 24 . Hyperlipidemia despite medical therapy ( fast LDL cholesterol &gt; 130 mg/dL , fast triglyceride &gt; 200 mg/dl ) . 25 . Chronic use systemic steroid , except use ≤5 mg prednisone daily , equivalent dose hydrocortisone , physiological replacement . 26 . Treatment antidiabetic medication insulin within 4 week enrollment . 23 . Use investigational agent within 4 week enrollment . 24 . Administration live attenuate vaccine ( ) within 2 month enrollment . 25 . Any medical condition , opinion investigator , interfere safe participation trial . 26 . Treatment immunosuppressive regimen time enrollment . 27 . A previous islet transplant . 28 . A previous pancreas transplant 29 . Inflammatory bowel disease . 30 . History intestinal obstruction . 31 . Previous major abdominal surgery . 32 . History peritonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>islet transplantation</keyword>
</DOC>